Merit Medical (MMSI) Systems announced that it has acquired Biolife Delaware, in a merger transaction through which Biolife has become a wholly-owned subsidiary of Merit. Biolife, which is headquartered in Sarasota, Florida, manufactures unique patented hemostatic devices under the brand names StatSeal and WoundSeal. The aggregate transaction consideration, paid in cash and assumption of Biolife liabilities, was approximately $120 million. This strategic acquisition positions Merit to provide clinicians with more products designed to standardize, simplify, and minimize post-procedure care and maintenance.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical Systems Shareholders Approve Key Proposals
- Merit Medical Systems: Revenue Model Update and Tariff Benefits Support Buy Rating
- Merit Medical announces Health Canada approval of WRAPSODY CIE
- Merit Medical releases 12-month efficacy results of WRAPSODY WAVE cohort
- Merit Medical’s Earnings Call: Growth Amid Challenges
